Your source of breaking information about Dutasteride also known as Avodart, Avolve, GI198745, GG745 or Duagen.
dutasteride duagen avodart avolve 
  Dutasteride.org is an independent clearinghouse for information about Dutasteride and is not associated or affiliated with GlaxoSmithKline or the Glaxo Group Limited. Avolve, Avodart and Duagen are registered trademarks of Glaxo Group Limited.  


What is Dutasteride

The Latest News

Dutasteride Studies

Dutasteride Safety Profile

FDA Approval Documents

Dutasteride Results


If you are interested in getting more information via email about the availability of Avodart please enter your email address below

hair loss MPB Dutasteridedutastiride avolve duagen
 
Dutasteride Results
 
These are the results of the GlaxoSmithKline testing of GI198745 otherwise known as Dutasteride for hair loss. These results were taken from the Phase II study required for FDA approval. The Phase III trials for hair loss are scheduled to begin in February/March of 2003 in the US. The drug is expected to be on the market for hair loss in 2006 if approved.
   
Before Dutasteride After Dutasteride

This graph shows that after six month of treatment, the hair counts measured in a 1 inch diameter circle increased by about ~96 hairs with 0.5mg Dutasteride, compared to about ~72 hairs with 5mg Finasteride. The hair counts increased significantly with an increase in dosage with the biggest gain being ~108 hairs with a dose of 2.5mg Dutasteride.

So compared to 5mg Finasteride (Proscar), 2.5 mg Dutasteride grew about 1.5 times as many hairs.

 
DUTASTERIDE PHASE 2 HAIR COUNTS
 
 
lowers DHT and promotes hair regrowth
Glaxo sells Avodart also know as Dutasteride   Avolve Avodart  GI198745  Duagen
 
  Copyright © 2002 Interactive Marketing Group - All Rights Reserved - email: info@dutasteride.org